ASP Isotopes

ASPI

Market cap $636M

WASHINGTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that, effective January 19, 2026, Paul Mann, the founder and Executive Chairman of ASP Isotopes, will resume his role as the Company's Chief Executive Officer and continue as Executive Chairman.

WASHINGTON, Nov. 28, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced the establishment of a new Photonics Chair at the University of Witwatersrand, Johannesburg (Wits University), through an endowment under a three-year donation agreement. Dr. Angela Dudley has been named as the inaugural incumbent of the new Photonics Chair.

WASHINGTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced it will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. (Eastern Time).

ASP Isotopes is transitioning to a revenue stage, but remains speculative, with Q3 results pending and limited current operations. ASPI's recent shipments of Ytterbium-176 and Silicon-28 could unlock $50–$70 million in potential revenues for 2026–2027, pending contract wins. The Renergen acquisition aims to cut enrichment costs by 96% and drive significant EBITDA growth by 2030, but execution risk remains.

WASHINGTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Quantum Leap Energy LLC (“QLE”), a wholly-owned subsidiary of ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced that QLE has commenced an offering of QLE's convertible notes in a private placement to accredited investors and certain non-U.S. persons. QLE has entered into a definitive convertible note purchase agreement with certain investors for an initial closing of US$64.3 million aggregate principal amount of QLE's convertible notes (the "Notes").

U.S. stock futures were higher this morning, with the Dow futures falling more than 150 points on Wednesday.

WASHINGTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the pricing of an underwritten public offering of 17,167,380 shares of its common stock for total gross proceeds of approximately $210.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on October 16, 2025, subject to satisfaction of customary closing conditions. All of the shares of common stock in the offering will be sold by the Company.

WASHINGTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Rare earth stocks have been ripping up the charts as trade tensions with China heat up again, and the Trump administration signals heavy support of the industry.

WASHINGTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a business development update, including a supply agreement for the largest quantity of enriched silicon-28 received by the Company to date and a strategic acquisition of a radiopharmacy in the United States to complement and expand the operations of PET Labs Pharmaceuticals (Pty) Ltd (“PET Labs”), the Company's South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production.